Stock Comparison

INSM vs JNJ

Insmed Inc vs Johnson & Johnson

The Verdict

INSM takes this one.

Winner

INSM

Insmed Inc

7.3

out of 10

Solid Pick

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$35.5B

Market Cap

N/A

-25.7

P/E Ratio

N/A

-210.5%

Profit Margin

N/A

-168.4%

Return on Equity

N/A

0.8

Debt-to-Equity

N/A

Aggressive

Overall Risk

Conservative

7.3

DVR Score

1.0

The Deep Dive

INSM7.3/10

Insmed (INSM) exhibits strong potential for future market leadership through its innovative pipeline and growing commercial footprint, driving a high growth score. The successful U.S. launch of BRINSUPRI and positive Phase 3b results for ARIKAYCE's ENCORE study are significant de-risking events and catalysts for revenue expansion within substantial addressable markets (NCFBE, IPF). Analyst upgrade...

Full INSM Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.